Your session is about to expire
← Back to Search
Ultrasound Diathermy
Sustained Acoustic Medicine Device Group 1 for Diathermy Mapping
Phase 1
Waitlist Available
Led By George Lewis, PHD
Research Sponsored by ZetrOZ, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
• Healthy Volunteer
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 - 4 hours
Awards & highlights
Study Summary
The purpose of this study is to measure diathermy performance of Sustained Acoustic Medicine Devices with commercially available ultrasound gel coupling patches.
Eligible Conditions
- Diathermy Mapping
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0 - 4 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 - 4 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ultrasound Diathermy (Degrees Centigrade)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Sustained Acoustic Medicine Device Group 1Experimental Treatment1 Intervention
Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
Group II: Sustained Acoustic Medicine Device Group 2Active Control1 Intervention
Patients receive treatment from the SAM Ultrasonic Diathermy Device 2 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sustained Acoustic Medicine
2022
Completed Phase 1
~60
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
ZetrOZ, Inc.Lead Sponsor
15 Previous Clinical Trials
1,211 Total Patients Enrolled
George Lewis, PHDPrincipal InvestigatorZetrOZ, Inc.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger